Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group

Minimal residual disease (MRD) as a marker of antileukemic drug efficacy is being used to assess risk status and, in some cases, to adjust the intensity of therapy. Within known prognostic categories, the determinants of MRD are not known. We measured MRD by flow cytometry at day 8 (in blood) and at...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Davies, Stella M., Borowitz, Michael J., Rosner, Gary L., Ritz, Kristin, Devidas, Meenakshi, Winick, Naomi, Martin, Paul L., Bowman, Paul, Elliott, James, Willman, Cheryl, Das, Soma, Cook, Edwin H., Relling, Mary V.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2008
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2265447/
https://ncbi.nlm.nih.gov/pubmed/18182569
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-09-114082
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados